PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported December 28, 2016

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01

Lack of Assurance of Sterility: Potential cracks in glass vials

Recall #
D-0226-2017
Affected scope
11,434 vials
Initiated
December 15, 2016
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Amgen, Inc. recalled AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For … - a moderate-severity action.

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For … was recalled by Amgen, Inc. in December 28, 2016. Reason: Lack of Assurance of Sterility: Potential cracks in glass vials. Check the official notice for the remedy. Verify recall #D-0226-2017 with the FDA Drug before acting.

The recall

Amgen, Inc. issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility: Potential cracks in glass vials.

Moderate
severity level
Class II
classification
December 28, 2016
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0226-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0226-2017) was formally reported on December 28, 2016, with the manufacturer initiating the action on December 15, 2016. It is classified under Moderate severity (Class II), with a current status of Terminated. Amgen, Inc. is listed as the recalling firm, operating out of Thousand Oaks, CA. Federal records list the affected scope as 11,434 vials.

The documented reason for this recall is: Lack of Assurance of Sterility: Potential cracks in glass vials Distribution data in the federal record shows the product reached: United States and Puerto Rico No foreign distribution.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

11,434 vials

Related Recalls

6

5 from same agency

Product description

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01

Reason for recall

Lack of Assurance of Sterility: Potential cracks in glass vials

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-0226-2017
Date reported December 28, 2016
Date initiated December 15, 2016
Recalling firm Amgen, Inc.
Firm location Thousand Oaks, CA
Affected scope 11,434 vials
Distribution United States and Puerto Rico No foreign distribution.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0226-2017) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01. Recalled by Amgen, Inc.. Units affected: 11,434 vials.
Why was this product recalled?
Lack of Assurance of Sterility: Potential cracks in glass vials
Which agency issued this recall?
This recall was issued by the FDA Drug on December 28, 2016. Severity: Moderate. Recall number: D-0226-2017.
Where was the recalled product distributed?
Distribution: United States and Puerto Rico No foreign distribution..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0226-2017) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 28, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.